ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Vasculitis"

  • Abstract Number: 1695 • ACR Convergence 2024

    Efficacy of Upadacitinib in Patients with Giant Cell Arteritis: Subgroup Analysis of the SELECT-GCA Phase 3 Trial

    Peter Merkel1, Arathi Setty2, Ricardo Blanco-Alonso3, Ravi Suppiah4, Thomas Daikeler5, Valerie Devauchelle6, Elisabeth Brouwer7, Hiromichi Tamaki8, Liu Meng2, Yang Yang2, Avani Joshi2, Charles Phillips2, Peter K. Wung2 and Cristina Ponte9, 1Division of Rheumatology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, 2AbbVie, North Chicago, IL, 3Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain, 4Health New Zealand, Te Toka Tumai Auckland, Auckland, New Zealand, 5university hospital, Basel, Switzerland, 6UBO, Brest, France, 7University Medical Center Groningen, Groningen, Netherlands, 8St. Luke's International Hospital, Tokyo, Japan, 9Unidade Local de Saúde Santa Maria, Serviço de Reumatologia e Doenças Ósseas Metabólicas, Lisboa, Portugal., Lisbon, Portugal

    Background/Purpose: Giant cell arteritis (GCA) is a chronic systemic vasculitis with limited targeted therapeutic options. The recent SELECT-GCA phase 3 trial demonstrated a favorable benefit-risk…
  • Abstract Number: 2496 • ACR Convergence 2024

    Clinical Features and Outcomes of Hydralazine-associated Vasculitis: A Case-Control Study

    Elif Ediboglu1, Samuel Falde1, Misbah Baqir1, Rodrigo Cartin-Ceba2 and Ulrich Specks1, 1Mayo Clinic, Rochester, MN, 2Mayo Clinic, Scottsdale, AZ

    Background/Purpose: We aimed to investigate the relationship between hydralazine and any form of vasculitis (small, medium, or large vessel), to describe clinical features and outcomes…
  • Abstract Number: 2520 • ACR Convergence 2024

    Prevalence and Incidence of Giant Cell Arteritis Among Medicare Fee-For-Service Beneficiaries: United States, 2014–2019

    Peter Merkel1, Yi Peng2, Patrick Zueger2, Clara Ziadeh3, Ana B. Romero4, Richard Thielen3 and Denise Kruzikas3, 1Division of Rheumatology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, 2AbbVie Inc, North Chicago, IL, 3AbbVie Inc., North Chicago, IL, 4AbbVie, North Chicago, IL

    Background/Purpose: Giant cell arteritis (GCA) is a vasculitis affecting individuals aged ≥50 years. Over 80% of patients with GCA are aged ≥70 years, reflecting a…
  • Abstract Number: 0720 • ACR Convergence 2024

    Impact of Systemic Vasculitides on Sexual Function: An Overlooked Aspect of Patient Care

    javier Merayo Chalico1, Ana Sarahí Mulia-Soto2, María Espinosa-León3, Victor Pimentel-Quiroz4, Ana Barrera-Vargas3 and Andrea Hinojosa-Azaola3, 1Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, CDMX, Mexico, 2Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Ciudad de México, Mexico, 3Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Mexico City, Mexico, 4Universidad Científica del Sur/Hospital Nacional Guillermo Almenara Irigoyen, Magdalena del Mar, Peru

    Background/Purpose: Systemic vasculitides comprise a group of inflammatory diseases involving multiple organ systems, significantly affecting various aspects of a patient's life, including their sexuality. Sexual…
  • Abstract Number: 0756 • ACR Convergence 2024

    Effectiveness and Safety of Tocilizumab in the Treatment of Polymyalgia Rheumatica: A Meta-Analysis

    Ali Raza Khan1, Nouman Shafique2, Abdul Qadeer1 and zaigham Shaukat1, 1Nishtar Medical University, Multan, Punjab, Pakistan, 2AdventHealth Orlando, Orlando, FL

    Background/Purpose: Giant Cell Arteritis (GCA) and Polymyalgia Rheumatica (PMR) are different manifestations of the same disease process. GCA is a vasculitis that affects large and…
  • Abstract Number: 0855 • ACR Convergence 2024

    Addition of Immunosuppressive Agents And/or Intravenous Immunoglobulin to Steroids in the Treatment of Susac Syndrome: A National Cohort Study

    Alexandra Kachaner1, Arthur Mageau1, Tiphaine Goulenok2, Chrystelle Francois2, Marie-Paule Chauveheid2, Thomas Papo1 and Karim Sacré1, 1Université Paris Cité, Paris, France, 2Assistance Publique Hôpitaux de Paris, Paris, France

    Background/Purpose: Susac syndrome (SuS) is an exceedingly rare microvasculopathy of the brain, retina and inner ear affecting young patients with potential lifelong sequelae. No randomized controlled…
  • Abstract Number: 1617 • ACR Convergence 2024

    Persistence of Imaging Abnormality in Patients with Large Vessel Vasculitis Despite Clinical Remission

    Luigi Boiardi1, Pierluigi Macchioni1, Francesco Muratore2, Chiara Marvisi1, Caterina Ricordi1, Annibale Versari1, Giulia Besutti1, Lucia Spaggiari1, Stefania Croci1 and Carlo Salvarani1, 1Azienda Sanitaria Locale, IRCSS, Reggio Emilia, Reggio Emilia, Italy, 2Unit of Rheumatology, Azienda USL - IRCCS di Reggio Emilia and University of Modena and Reggio Emilia, Reggio Emilia, Italy

    Background/Purpose: Aim of our study was to evaluate the persistence of imaging abnormalities in patients with Takayasu (TAK) and large vessel giant cell arteritis (LV-GCA)…
  • Abstract Number: 1884 • ACR Convergence 2024

    VIVA QI: Vaccination In Vasculitis: Applying a Quality Improvement Approach

    Stephen Williams, Stephanie Garner and Aurore Fifi-Mah, University of Calgary, Calgary, AB, Canada

    Background/Purpose: The vasculitides are rare but serious conditions that are characterized by the destructive inflammation of the blood vessels. Patients living with vasculitis are often considered…
  • Abstract Number: 2497 • ACR Convergence 2024

    Clinical Characteristics and Outcomes of Hydralazine-induced ANCA-associated Vasculitis. a Single Center Retrospective Cohort Analysis from the US

    Muhammad Shamim1, Mazen Allouni2, Haseeb Chaudhary3, Ansaam Daoud4, Loai Dweik5, Hashim Syed6 and Omer Pamuk7, 1University Hospitals/ Case Western Reserve University, Cuyahoga Falls, OH, 2Case Western Reserve, University Hospitals, Cleveland Medical Center, Cleveland, OH, 3Case Western Reserve University, Westlake, OH, 4Case Western Reserve University/University Hospitals, Akron, OH, 5Cleveland Clinic Akron General Internal Medicine, Akron, OH, 6Case Western/ UH, Cleveland, 7University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH

    Background/Purpose: Hydralazine-induced ANCA-associated vasculitis (HIAAV) is a rare clinical problem.  There is paucity of data regarding clinical features, treatment, and prognosis of hydralazine-induced AAV in…
  • Abstract Number: 2521 • ACR Convergence 2024

    Clinicopathologic Associations Between Macrophage Location and Functional Profile in Giant Cell Arteritis

    Michael Putman1, Nader Khalidi2, Carol Langford3, Curry Koening4, Christian Pagnoux5, David Cuthbertson6, Carol McAlear7 and Peter Merkel7, and the Vasculitis Clinical Research Consortium (VCRC), 1The Medical College of Wisconsin, Milwaukee, WI, 2McMaster University, Hamilton, ON, Canada, 3Cleveland Clinic, Moreland Hills, OH, 4University of Texas Dell Medical School, Austin, TX, 5Mount Sinai Hospital, Toronto, ON, Canada, 6University of South Florida, Tampa, FL, 7University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Macrophages play a central role in the pathogenesis of giant cell arteritis (GCA), but few studies have correlated macrophage phenotype or topography from temporal…
  • Abstract Number: 0724 • ACR Convergence 2024

    Incidence of ANCA-Associated Vasculitis in a Northern Spanish Health Region Between 2000-2023: A Populatio-based Study

    Fabricio Benavides1, Alba Herrero-Morant2, Salma Al Fazazi3, Vanesa Calvo-Rio4, Mónica Renuncio-García5, Adrián Martín-Gutiérrez6, Amparo Sánchez-López7, Claudia Poo-fernandez7, Clara Escagedo-Cagigas7, Maria Rodríguez-Vidriales1 and Ricardo Blanco-Alonso8, 1Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain, 2Hospital Universitario Marqués de Valdecilla, Ontinyent, Cantabria, Spain, 3Hospital Universitario Virgen de la Victoria, Málaga, Andalucia, Spain, 4Valdecilla Hospital, Santander, Cantabria, Spain, 5Division of Immunology, Hospital Universitario Marqués de Valdecilla, Immunopathology Group, IDIVAL, Santander, Spain, 6Hospital Universitario Marques de Valdecilla, IDIVAL, Renedo de Piélagos, Cantabria, Spain, 7Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, 8Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain

    Background/Purpose: Anti-neutrophil cytoplasmic antibodies (ANCA) associated vasculitis (AAV) is a group of vasculitis that affect small vessels. Includes Granulomatosis with polyangiitis (GPA), Eosinophilic granulomatosis with…
  • Abstract Number: 0757 • ACR Convergence 2024

    Regulation of Macrophage Differentiation by Serum Adiponectin: A Novel Mechanism to Increase Alternatively Activated Macrophages During the Remission Phase of Giant Cell Arteritis

    Anna Kernder1, Lena Noack1, Adina Morar1, Lara Burg2, Torsten Lowin1, Dennis Bleck1, matthias schneider1, Jörg Distler3, Georg Pongratz4 and Valentin S. Schäfer5, 1Clinic for Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine-University, Düsseldorf, Germany., Düsseldorf, Germany, 2Department of Rheumatology and Clinical Immunology, Clinic of Internal Medicine III, University Hospital of Bonn, Germany, Bonn, Germany, 3Universitätsklinikum Düsseldorf and Heinrich-Heine-Universität Düsseldorf, Duesseldorf, Germany, 4Clinic for Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine-University, Düsseldorf, Germany., Regensburg, Germany, 5University Hospital Bonn, Bonn, Germany

    Background/Purpose: The immunopathogenesis of giant cell arteritis (GCA) remains unclear. It is known that monocytes are recruited from peripheral blood, infiltrate the vessel wall, and…
  • Abstract Number: 0916 • ACR Convergence 2024

    Isocitrate Dehydrogenase 2 Mutations Are Associated with Autoimmune Rheumatologic Diseases in Chronic Myelomonocytic Leukemia

    Mahmut Kaymakci1, Anuya Natu2, Clifford Csizmar2, Terra Lasho2, Christy Finke2, Abhishek Mangaonkar1, Aref Al-Kali1, Hassan Alkhateeb1, Jenna Fernandez2, Matthew Koster1, Cornelia Weyand2, Mrinal Patnaik1 and Kenneth Warrington1, 1Mayo Clinic, Rochester, MN, 2Mayo Clinic, Rochester

    Background/Purpose: Somatic mutations occurring in the hematopoietic system can be associated with concomitant hematologic and inflammatory diseases. Chronic myelomonocytic leukemia (CMML) is a hematologic neoplasm…
  • Abstract Number: 1620 • ACR Convergence 2024

    Unveiling of a New Molecular Imaging Biomarker? Vascular Adhesion Protein-1 and [68Ga]Ga-DOTA-Siglec-9 PET/CT in Detecting Giant Cell Arteritis Relapse

    Simon Petzinna1, Jim Küppers2, Benedikt Schemmer2, Anna Kernder3, Claus Juergen Bauer1, Pantelis Karakostas1, Denada Bruci3, Adina Morar3, Anja Winklbauer2, Markus Essler2 and Valentin S. Schäfer2, 1Clinic of Internal Medicine III, Department of Rheumatology, University Hospital of Bonn, Bonn, Germany, Bonn, Germany, 2University Hospital Bonn, Bonn, Germany, 3University Hospital Düsseldorf, Düsseldorf, Nordrhein-Westfalen, Germany

    Background/Purpose: Vascular adhesion protein-1 (VAP-1) is a transmembrane adhesion molecule with oxidative deamination functionality, which is expressed in vascular smooth muscle cells and endothelial cells.…
  • Abstract Number: 1896 • ACR Convergence 2024

    The Prevalence, Incidence, Risk Factors and Time to Diagnosis of Behcet’s Syndrome in England: A Retrospective Nested Case Control Study in Clinical Practice Research Datalink and Hospital Episode Statistics

    Priyanka Chandratre1, Joht Chandan2, Ben Hammond3, Rasiah Thayakaran3, Samuel Cusworth3, Nicola Adderley3 and Deva Situnayake4, 1The Ottawa Hospital and Ottawa Hospital Research Institute (OHRI), Ottawa, ON, Canada, 2Institute of Applied Health Research, Birmingham, United Kingdom, 3Institute of Applied Health Research, University of Birmingham, Birmingham, United Kingdom, 4Sandwell and West Birmingham NHS Trust, Birmingham, United Kingdom

    Background/Purpose: The prevalence and incidence of Behcet’s syndrome (BS) in the UK is unknown at an unselected population level. BS may be associated with phenotypically…
  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • …
  • 35
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology